Evolus signs exclusive deal with Symatese for four dermal fillers in Europe; issues 610,000 shares

Evolus, Inc.

Exclusive rights to distribute Lift, Smooth, Sculpt, and Lips fillers under Estyme® brand in 50 European countries.
Consideration includes 610,000 common shares to Symatese and up to €3.1M in milestone payments.
European regulatory approvals expected H2 2024; commercialization targeted for 2025.
No material impact on 2025 profitability target; company to pre-announce Q4/FY 2023 results and 2024 guidance in January.
Evolus licenses Nuceiva® to Symatese for France; sub-licenses Estyme® distribution in France to Symatese subsidiary.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Evolus, Inc. entered into License, Supply and Distribution Agreement with Symatese Aesthetics S.A.S. valued at 610,000 shares of the Company’s common stock (effective 2023-12-20).

Action: entry
Agreement: license
Counterparty: Symatese Aesthetics S.A.S.
Value: 610,000 shares of the Company’s common stock
Effective: 2023-12-20

Exact text from the filing

On December 20, 2023, Evolus Pharma B.V. (“Evolus Europe”), a wholly owned subsidiary of Evolus, Inc. (the “Company”) and Symatese Aesthetics S.A.S. (“Symatese”), entered into a License, Supply and Distribution Agreement (the “Agreement”), pursuant to which Symatese granted to Evolus Europe an exclusive right to commercialize and distribute four dermal filler product candidates

View on SEC.gov

280 material agreements filed in the last 30 days. Browse all material agreements →

Evolus, Inc. filing history →

Source: SEC EDGAR

accession 0001570562-23-000119

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.